Paradigm Genetics has received a patent for a gene targeting process related to antibiotics.

The company said the process involves how fungi produce lysine, a nutrient necessary for fungi to thrive. Paradigm added that the chemical compound discovery could lead to the development of less toxic fungicides.

Paradigm (Nasdaq: PDGM) said it used its proprietary discovery technology to identify the target.